Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Gains from Sales and Divestitures (2016 - 2025)

Ironwood Pharmaceuticals' Gains from Sales and Divestitures history spans 16 years, with the latest figure at $260063.0 for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 86.21% to $260063.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $260063.0, a 86.21% decrease, with the full-year FY2025 number at $260063.0, down 86.21% from a year prior.
  • Gains from Sales and Divestitures hit $260063.0 in Q4 2025 for Ironwood Pharmaceuticals, down from $1.9 million in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for IRWD hit a ceiling of $1.9 million in Q4 2024 and a floor of $189118.0 in Q4 2023.
  • Historically, Gains from Sales and Divestitures has averaged $559132.6 across 5 years, with a median of $246710.0 in 2022.
  • Biggest five-year swings in Gains from Sales and Divestitures: surged 897.46% in 2024 and later plummeted 86.21% in 2025.
  • Tracing IRWD's Gains from Sales and Divestitures over 5 years: stood at $213400.0 in 2021, then grew by 15.61% to $246710.0 in 2022, then decreased by 23.34% to $189118.0 in 2023, then surged by 897.46% to $1.9 million in 2024, then plummeted by 86.21% to $260063.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for IRWD at $260063.0 in Q4 2025, $1.9 million in Q4 2024, and $189118.0 in Q4 2023.